---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-24-000055"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2024-06-17T23:59:59+00:00"
generated_at: "2026-06-01T04:07:23.901706+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Keros reports durable transfusion independence in Phase 2 MDS trial; plans registrational Phase 3

## Summary
- Overall erythroid response 55.6% (45/81) in modified ITT patients; 41.3% (26/63) of TI-evaluable achieved ≥8-week transfusion independence.
- Median duration of TI not reached; 42.3% (11/26) of TI responders had responses >1 year, all ongoing as of April 3, 2024.
- In MF Phase 2, 60.6% (20/33) of transfusion-dependent patients had reduced transfusion burden; 52.9% (9/17) with large spleens had volume reductions at Week 24.
- Preclinical MF model data shows elritercept promotes erythropoiesis, mitigates anemia, and improves muscle mass/function.
- Company plans to initiate a registrational Phase 3 trial in lower-risk MDS following positive FDA feedback.

## SEC filing metadata
- accession: 0001664710-24-000055
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2024-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471024000055/0001664710-24-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471024000055/kros-20240617.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-24-000055
- JSON: https://secwatch.observer/filing/0001664710-24-000055.json
- Plain text: https://secwatch.observer/filing/0001664710-24-000055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.